mogamulizumab
Showing 1 - 9 of 9
Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome Trial in Ann Arbor (Pembrolizumab, Mogamulizumab)
Not yet recruiting
- Cutaneous T Cell Lymphoma
- Fungoides Mycosis Sezary Syndrome
- Pembrolizumab
- Mogamulizumab
-
Ann Arbor, MichiganUniversity of Michigan Comprehensive Cancer Center
Jul 13, 2023
T Cell Lymphoma Trial in New Haven (Mogamulizumab, DA-EPOCH Protocol)
Not yet recruiting
- T Cell Lymphoma
- Mogamulizumab
- DA-EPOCH Protocol
-
New Haven, ConnecticutYale Smilow Cancer Hospital
Aug 14, 2023
Cutaneous T Cell Lymphoma, Mycosis Fungoides Trial (Mogamulizumab, Brentuximab vedotin)
Not yet recruiting
- Cutaneous T Cell Lymphoma
- Mycosis Fungoides
- Mogamulizumab
- Brentuximab vedotin
- (no location specified)
Dec 7, 2022
Sezary Syndrome, Mycosis Fungoides Trial in Stanford (Mogamulizumab, LD TSEBT)
Recruiting
- Sezary Syndrome
- Mycosis Fungoides
- Mogamulizumab
- LD TSEBT
-
Stanford, CaliforniaStanford Cancer Center
Oct 19, 2022
Adult T-Cell Lymphoma/Leukemia, Sezary Syndrome, Mycosis Fungoides Trial run by the NCI (Recombinant human Interleukin-15
Completed
- Adult T-Cell Lymphoma/Leukemia
- +2 more
- Recombinant human Interleukin-15 (rhIL-15)
- Mogamulizumab
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Dec 9, 2022
Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Adult T-Cell
Recruiting
- Recurrent Adult T-Cell Leukemia/Lymphoma
- +3 more
- Cyclophosphamide
- +5 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 18, 2022
Cutaneous T-Cell Lymphoma, Relapsed, Cutaneous T-Cell Lymphoma Refractory Trial in Worldwide (Mogamulizumab)
Recruiting
- Cutaneous T-Cell Lymphoma, Relapsed
- Cutaneous T-Cell Lymphoma Refractory
- Mogamulizumab
-
Duarte, California
- +17 more
Jul 19, 2022
NSCLC Trial in United States (mogamulizumab, Docetaxel)
Completed
- Non-Small Cell Lung Cancer
- mogamulizumab
- Docetaxel
-
Lafayette, Indiana
- +4 more
Apr 24, 2018